




RealRate

PHARMACEUTICAL 2020

Mersana Therapeutics Inc
Rank 109 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Mersana Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mersana Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Mersana Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 308%, being 70% points above the market average of 238%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	101,326	Assets	107,541
Cost of Goods Sold	0	Liabilities	29,223
Intangible Assets	0	Expenses	72,323
Liabilities, Current	24,070	Revenues	42,123
Liabilities, Non-Current	5,153	Stockholders Equity	78,318
Other Assets	4,051	Net Income	-28,208
Other Compr. Net Income	33	Comprehensive Net Income	-28,192
Other Expenses	0	BaseVar	126,618
Other Liabilities	0	ECR before LimitedLiability	208%
Other Net Income	1,992	Economic Capital Ratio	308%
Other Revenues	42,123		
Property and Equipment	2,164		
Research and Development	55,040		
Selling, General and Administrative Expense	17,283		